In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease
Table 3
Medical therapy characteristics.
Comedication
Variable
All patients
Stable CAD
ACS
value
Number of patients
1456
895
561
—
Patients with follow-up
1340 (92.0%)
836 (93.4%)
504 (89.8%)
0.014
Preloading
No preloading
738 (50.7%)
523 (58.4%)
215 (38.3%)
<0.001
Clopidogrel
385 (26.4%)
289 (32.3%)
96 (17.1%)
Ticagrelor
310 (21.3%)
74 (8.3%)
236 (42.1%)
Prasugrel
23 (1.6%)
9 (1.0%)
14 (2.5%)
DAPT maintenance after angioplasty
Clopidogrel
862 (59.2%)
665 (74.3%)
197 (35.1%)
<0.001
Ticagrelor
552 (37.9%)
212 (23.7%)
340 (60.6%)
Prasugrel
42 (2.9%)
18 (2.0%)
24 (4.3%)
Anticoagulation
No anticoagulation
1379 (94.7%)
850 (95.0%)
529 (94.3%)
0.180
Vitamin K antagonist
21 (1.4%)
15 (1.7%)
6 (1.1%)
NOAC
54 (3.7%)
30 (3.4%)
24 (4.3%)
Others
2 (0.1%)
0 (0.0%)
2 (0.4%)
DAPT duration
1 month
34 (2.3%)
27 (3.0%)
7 (1.3%)
<0.001
2 months
5 (0.3%)
1 (0.1%)
4 (0.7%)
3 months
50 (3.4%)
22 (2.5%)
28 (5.0%)
4 months
2 (0.1%)
1 (0.1%)
1 (0.2%)
5 months
2 (0.1%)
1 (0.1%)
1 (0.2%)
6–9 months
445 (30.6%)
364 (40.8%)
81 (14.5%)
10–12 months
810 (55.7%)
419 (46.9%)
391 (69.8%)
>12 months
101 (7.0%)
57 (6.4%)
44 (7.9%)
Unknown
4 (0.3%)
1 (0.1%)
3 (0.5%)
Time to discharge in days
2.5 ± 4.9
1.8 ± 4.1
3.6 ± 5.8
<0.001
Time to follow-up or event in months
12.4 ± 0.7
12.4 ± 0.6
12.4 ± 0.9
0.513
DAPT interruption (<6 months for stable CAD, <12 months for ACS)
